BrainsWay Ltd. (BWAY)
NasdaqGM · USD · Healthcare · Medical Devices
$11.23 (+0.18%) as of
Key statistics
- Market cap
- 452.04M
- P/E (TTM)
- 48.83
- Forward P/E
- 22.16
- EPS (TTM)
- 0.23
- Dividend yield
- 0.00%
- 52-week range
- 7.14 – 17.40
- Beta
- 0.10
- Revenue (TTM)
- 60.7M
- Profit margin
- 15.56%
- Analyst target
- $19.27
- Volume
- 1.56k
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Jerusalem, Israel
- Employees
- 129
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.